Cite
Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.
MLA
Radujkovic, Aleksandar, et al. “Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.” Cancers, vol. 12, no. 12, Dec. 2020, p. 3683. EBSCOhost, https://doi.org/10.3390/cancers12123683.
APA
Radujkovic, A., Boch, T., Nolte, F., Nowak, D., Kunz, C., Gieffers, A., Müller-Tidow, C., Dreger, P., Hofmann, W.-K., & Luft, T. (2020). Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. Cancers, 12(12), 3683. https://doi.org/10.3390/cancers12123683
Chicago
Radujkovic, Aleksandar, Tobias Boch, Florian Nolte, Daniel Nowak, Claudia Kunz, Alexandra Gieffers, Carsten Müller-Tidow, Peter Dreger, Wolf-Karsten Hofmann, and Thomas Luft. 2020. “Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.” Cancers 12 (12): 3683. doi:10.3390/cancers12123683.